Natural Health Trends Corp. is facing a significant challenge as it has received a notification from Nasdaq indicating that it no longer meets the minimum bid price requirement for continued listing on the exchange. This notification, dated November 16, 2026, is based on the company's common stock closing bid price falling below $1.00 per share for 30 consecutive business days.
The notice from Nasdaq does not immediately affect the listing of Natural Health Trends' common stock, which continues to be traded under the symbol 'NHTC' on the Nasdaq Capital Market. However, the company has been granted an initial compliance period of 180 calendar days to regain compliance with the minimum bid price requirement.
About Natural Health Trends Corp.
Natural Health Trends Corp. operates within the wholesale miscellaneous nondurable goods sector, as classified under SIC code 5190. The company is listed on the Nasdaq stock exchange under the ticker symbol NHTC. As a smaller reporting company, it has faced various market challenges that have affected its stock performance.
Details from the Filing
According to the SEC filing (accession number 0001437749-26-037723), the company has until May 17, 2027, to meet the minimum bid price requirement. To regain compliance, the closing bid price of its common stock must be at least $1.00 per share for a minimum of 10 consecutive business days during this compliance period. Nasdaq may also require the company to maintain compliance for a longer period, generally not exceeding 20 consecutive business days.
The filing also mentions that if Natural Health Trends decides to implement a reverse stock split to meet the requirement, this action must be completed no later than 10 business days prior to the compliance deadline.
Potential Impact
This situation could affect various stakeholders, including investors and company management. If the company fails to regain compliance by the deadline, it may be eligible for an additional compliance period, provided it meets other listing standards. However, if it does not qualify for this extension, Nasdaq may initiate delisting procedures, which could significantly impact the company's market presence and investor confidence.
What's Next?
The company intends to monitor its stock price closely and evaluate options to regain compliance with Nasdaq's listing requirements. Future filings may provide updates on its compliance efforts and any decisions regarding a reverse stock split.
Read Next
Alps Group Regains Compliance with Nasdaq Listing Standards
Ainos, Inc. Receives Nasdaq Delisting Notice Over Equity
Compass Therapeutics Receives Nasdaq Deficiency Notice
60 Degrees Pharmaceuticals Faces Nasdaq Delisting Risk
Biofrontera Inc. Faces Nasdaq Delisting Due to Low Stock Price
Senti Biosciences dismisses KPMG, appoints new auditor KNAV










